Skip to main content

Advertisement

SpringerLink
Log in

The Role of c-erbB-2 Expression on the Survival of Patients with Small-Cell Lung Cancer

  • LUNG CANCER
  • Published:
Lung Aims and scope Submit manuscript

Abstract

The aim of this study was to determine the incidence and role of c-erbB-2 overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of SCLC. A chart review for demographic and clinical data was performed on patients with SCLC diagnosed between 1998 and 2004. c-erbB-2 overexpression was evaluated using immunohistochemistry performed on archival paraffin-embedded specimens. Sixty-seven patients with SCLC were identified (6 females, 61 males; median age- 56.5 yr, range-34–75) all of whom had adequate tissue specimens available for c-erB-2 testing. Of the 67 specimens, 12 (17.9%) showed c-erbB-2 overexpression. Seventy-five of the cases were positive for c-erbB-2, had extensive disease. The median overall survival of patients with SCLC whose tumors were positive and negative for c-erbB-2 were 8 ± 0.9 months (95%CI 6.3–9.7) and 11 ± 1.5 months (95%CI 8.0–14.0), respectively. c-erbB-2 overexpression detected using immunohistochemistry is observed in 17.9% of patients with SCLC and has statistically significant prognostic value. Our findings suggest that c-erbB-2 may be a potential target for site-specific immunotherapy in SCLC. Considering one technique examined, further molecular investigation is needed to confirm these preliminary findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Artega CL (1995) Epidermal growth factor receptors and c-erbB-2 in human lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds) Lung Cancer. Principles and practice. Lippincott, Philadelphia, pp 107–121

    Google Scholar 

  2. Coombs LM, Pigott DA, Sweeney E, et al. (1991) Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63:601–608

    PubMed  CAS  Google Scholar 

  3. Elias AD (1997) Small cell lung cancer: state-of-the-art therapy in 1996. Chest 12:251s–258s

    Google Scholar 

  4. Fu XL, Zhu XZ, Wang LJ, et al. (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23:143–152

    Article  PubMed  CAS  Google Scholar 

  5. Giatromanolaki A, Koukourakis MI, O’Byrne K, et al. (1996) Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis, Anticancer Res l6:3819–3825

    Google Scholar 

  6. Hall PA, Hughes CM, Staddon SL, et al. (1990) The c-erbB-2 proto-oncogene in human pancreatic cancer. J Pathol 161:195–200

    Article  PubMed  CAS  Google Scholar 

  7. Han H, Lanreneu RJ, et al. (2002) Prognostic value of immunohistochemical expression of p53, HER2/neu, and bcl-2 in stage I non-small cell lung cancer. Hum Pathol 33:105–110

    Article  PubMed  CAS  Google Scholar 

  8. Hanna W, Kahn HJ, Trudeau M (1999) Evaluation of Her-2/neu (erbB-2) status in breast cancer: From bench to bedside. Mod Pathol 12:827–834

    PubMed  CAS  Google Scholar 

  9. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A (2001) Protein overexpression and gene amplification of c-erbB-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 14:556–562

    Article  PubMed  CAS  Google Scholar 

  10. Ihde DC (1992) Chemotherapy of lung cancer. N EngI J Med 327:1434–l441

    Article  CAS  Google Scholar 

  11. Kay EW, Mulcahy H, Walsh CB, Leader M, O’Donoghue D (1994) Cytoplasmic c-erbB-2 protein expression correlates with survival in Duke’ a post B colorectal carcinoma. Histopathology 25:455–461

    CAS  Google Scholar 

  12. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48:6–29

    PubMed  CAS  Google Scholar 

  13. Micke P, Hengstler JG, Ros R, et al. (2001) c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92:474–479

    Article  PubMed  CAS  Google Scholar 

  14. Peethambaram PP, Cliby WA, Lubiniecki G, et al. (2003) HER2/neu expression in ovarian cancer: Pre and postexposure to platinum chemotherapy. Gynecol Oncol 89:99–104

    Article  PubMed  CAS  Google Scholar 

  15. Pfeiffer P, Clausen PP, Andersen K, Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74:86–91

    PubMed  CAS  Google Scholar 

  16. Saad RS, Liu Y, Han H, Landreneau RJ, Silverman JF (2004) Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Mod Pathol 17:1235–1242

    Article  PubMed  CAS  Google Scholar 

  17. Schechter AL, Stem DF, Vaidyanathan L, et al. (1984) The neu oncogene encode: An erbB related gen encoding a 185,000-Mr tumour antigen. Nature 312:513–516

    Article  PubMed  CAS  Google Scholar 

  18. Schneider PM, Hung MC, Chiocca SM, et al. (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968–4971

    PubMed  CAS  Google Scholar 

  19. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T (1989) Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 49:6474–6479

    CAS  Google Scholar 

  20. Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  21. Sloman A, D’Amco F, Yousem SA (1996) Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study. Arch Pathol Lab Med 120:465–472

    PubMed  CAS  Google Scholar 

  22. Stahel RA, Ginsberg R, Havemann K (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126

    Article  Google Scholar 

  23. Sugg SL, Ezzat S, Zheng L, et al. (1998) Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin Endocrinol (Oxf) 49:629–637

    Article  CAS  Google Scholar 

  24. Tetu B, Brisson J (1994) Prognostic significance of HER- 2/neu oncoprotein & expression in node positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 73:2359–2365

    Article  PubMed  CAS  Google Scholar 

  25. Treish I, Schwartz R, Lindley C (2000) Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 57:2063–2076

    PubMed  CAS  Google Scholar 

  26. Weiner DB, Nordberg J, Robinson R (1990) Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50:421–425

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MKP Blv Hukukcular Sit. B-Blok No. l5 Kocasinan, 38090, Kayseri, Turkey

    Ozlem Canoz

  2. Department of Pathology, Erciyes University Medical Faculty, Kayseri, Turkey

    Ozlem Canoz & Vedat Arsav

  3. Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey

    Metin Ozkan, Ozlem Er & Mustafa Altinbas

  4. Department of Medical Oncology, Suleyman Demirel University Medical Faculty, Toparta, Turkey

    H. Senol Coskun

  5. Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey

    Serdar Soyuer

Authors
  1. Ozlem Canoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Metin Ozkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vedat Arsav
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozlem Er
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Senol Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Serdar Soyuer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mustafa Altinbas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ozlem Canoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canoz, O., Ozkan, M., Arsav, V. et al. The Role of c-erbB-2 Expression on the Survival of Patients with Small-Cell Lung Cancer. Lung 184, 267–272 (2006). https://doi.org/10.1007/s00408-005-2591-y

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-005-2591-y

Keywords

Search

Navigation